The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

systemic lupus erythematosus

25th Feb 2025

A plain language summary of Part A of the LILAC study of litifilimab for treating systemic lupus erythematosus

This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib.Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.

27th Jun 2023

systemic lupus erythematosus

A plain language summary of Part A of the LILAC study of litifilimab for treating systemic lupus erythematosus

Plain Language Summary: what can clinical studies tell us about evobrutinib, a potential treatment for multiple sclerosis